Post-approval outcomes of voretigene neparvovec (Luxturna®) retinal gene therapy: A systematic review and meta-analysis.

چکیده

Voretigene neparvovec is the first approved gene therapy for inherited retinal disease and is indicated for patients with biallelic RPE65 gene mutations. This systematic literature review examines its safety and efficacy in the context of emerging long-term and post-approval data. Random-effects…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• شبکیه